FSUE Moscow Endocrine Plant completed the reconstruction of the workshop for the production of lyophilized and liquid injectable drugs, as well as prefilled single-use syringes and eye drops in vials, and in September begins to release the first batches of drugs necessary to meet the needs of the regions of the country. Most of the products are included in the list of vital and essential drugs, such as: "Droperidol, solution for injections, 2.5 mg/ l", "Heparin, solution for intravenous and subcutaneous administration, 5000 IU", "Atropine eye drops 1%", "Chorionic gonadotropin, lyophilisate for the preparation of a solution for intramuscular injection, 500 IU, 1000 IU, 1500 IU and 5000 IU","Lornoxicamyliophilisate for the preparation of a solution for intravenous and intramuscular administration, 8 mg "and others. The area of the reconstructed premises of the workshop is more than 2800 square meters. In the framework of a joint project with the Ministry of Industry and Trade of Russia on the reconstruction of the workshop of sterile drugs, the obsolete equipment was replaced by the newest high-tech equipment of leading foreign manufacturers, such as: MARCHESINI (Italy), GEA (Germany), DARA and OPTREL (Spain). The premises of the workshop, ventilation, water treatment comply with the norms and requirements of GMP standards. - In order to confirm compliance, inspections with the participation of foreign experts will be carried out in the near future. As a result of the reconstruction, the increase in production amounted to - Injection drugs and eye drops in vials - 20.8 million units in a year; - Injectable drugs in single-use syringes (new production) - 30.0 million units in a year; - Lyophilized preparations in vials - 3.9 million units in a year.
Implementation of the investment project of the Ministry of Industry and Trade of Russia and the Moscow Endocrine Plant for the reconstruction of the injection solution production workshop.
29 August 2019
Comment type is not specified in the component properties.